[en] P aeruginona infections need accurate antimicrobial susceptibility data, as treatment mainly relies on antibiotic efficiency in debilitated patients. Vitek 2, a popular automated susceptibility testing method, was compared with Etest to assess its reliability on 150 Belgian P. aeruginonas isolates. Vitek 2 and Etest exhibited a high degree of concordance, but some discrepancies in clinical category were evident for cefepime (high minor and borderline very major error rate) and for piperacillin/tazobactam (high very major error rate). Vitek 2 appears to yield valuable information to the clinician concerning the antimicrobials amikacin, ceftazidime, ciprofloxacin and meropenem, in the setting of pseudomonas infection. For cefepime and piperacillin/tazobactam, a confirmatory testing by means of disk diffusion is worth considering.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Saegeman, V.; UZ Gasthuisberg, KULeuven > Microbiologie
Huynen, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Microbiologie médicale
Colaert, J.
Melin, Pierrette ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Microbiologie médicale et virologie médicale
Verhaegen, J.; UZ Gasthuisberg, KULeuven > Microbiologie
Language :
English
Title :
Susceptibility testing of pseudomonas aeruginosa by the Vitek 2 system: A comparison with Etest results
Rello J, Jubert P, Valles J et al. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Inf Dis. 1996; 23: 973-8.
Steward C, Mohammed J, Swenson J et al. Antimicrobial Susceptibility Testing of Carbapenems: Multicenter Validity Testing and Accuracy Levels of Five Antimicrobial Test Methods for Detecting Resistance in Enterobacteriaceae and Pseudomonas aeruginosa Isolates. J Clin Microbiol. 2003; 41(1): 351-8.
Celis R, Torres A, Gatell JM et al. Nosocomial pneumonia: a multivariate analysis of risks and prognosis. Chest 1988; 93: 318-24.
Torres A, Aznar R, Gatell JM et al. Incidence, risks, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis. 1990; 142: 523-8.
Doern G, Brueggemann A, Perla R et al. Multicenter laboratory evaluation of the bioMerieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 1997; 35(8): 2115-9.
Barry J, Brown A, Ensor V et al. Comparative evaluation of the Vitek advanced expert system (AES) in five UK hospitals. J Antimicrob Chemother. 2003; 51: 1191-202.
Livermore D, Struelens M, Amorim J et al. Multicenter evaluation of the Vitek 2 advanced expert system for interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother. 2002; 49: 289-300.
Leclercq R, Nicolas-Chanoine M-H, Nordmann P et al. Multicenter Evaluation of an Automated System Using Selected Bacteria That Harbour Challenging and Clinically Relevant Mechanisms of Resistance to Antibiotics. Eur J Clin Microbiol Infect Dis. 2001; 20: 626-35.
Cantón R, Perez-Vazquez M, Oliver A et al. Validation of the Vitek 2 and the advance expert system with a collection of Enterobacteriaceae harbouring extended spectrum or inhibitor resistant β-lactamases. Diagn Microbiol Infect Dis. 2001; 41: 65-70.
Karlowsky J, Weaver M, Thornsberry C, Dowzicky M, Jones M, Sahm D. Comparison of Four Antimicrobial Susceptibility Testing Methods To Determine the In Vitro Activities of Piperacillin and Piperacillin-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2003; 41(7): 3339-43.
Burns J, Saiman L, Whittier S et al. Comparison of two commercial systems (Vitek and MicroScan WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis. 2001; 39: 257-260.
Chandler LJ, Poulter M, Reisner B, Woods G. Clinical evaluation of the Vitek automated system with cards GNS 122 and 127 and VTK-R07.01 software for antimicrobial susceptibility testing of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2002; 42: 71-3.
Jones R, Biedenbach D, Marshall S, Pfaller M, Doern G. Evaluation of the Vitek System to Acurrately Test the Susceptibility of Pseudomonas aeruginosa Clinical Isolates Against Cefepime. Diagn Microbiol Infect Dis. 1998; 32: 107-10.
Jones R, Marshall S, Zerva L. Critical Evaluation of the Vitek GNS-F6 Card Results Compared to Standardized, Reference Susceptibility Test Methods. Diagn Microbiol Infect Dis. 1997; 28: 35-40.
Doern G, Vautour R, Gaudet M, Levy B. Clinical Impact of Rapid In Vitro Susceptibility Testing and Bacterial Identification; J Clin Microbiol. 1994; 32: 1757-62.
Biedenbach DJ, Jones RN. Interpretive Errors Using an Automated System for the Susceptibility Testing of Imipenem an Aztreonam. Diagn Microbiol Infect Dis. 1995; 21: 57-60.
National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - Sixth Edition: Approved standard M7-A6, NCCLS, Villanova, PA, USA (2003).
Jorgensen J & Ferraro M. Antimicrobial susceptibility testing: general principles and contemporary practices. Clin Infect Dis. 1998; 26: 973-80.
Elder B. Verification and Validation of Procedures in the Clinical Microbiology Laboratory. Clinical microbiology newsletter 1997; 19(20): 153-60.
Glupczynski Y, Delmée M, Goossens H et al. Distribution and Prevalence of antimicrobial resistance among Gram-negative isolates in intensive care units (ICU) in Belgian hospitals between 1996 and 1999. Acta Clin Belg. 2001; 56(5): 297-306.
Schwebke J, Waites K, Beverly A et al. Inaccuracy of automated susceptibility testing for cefepime against Pseudomonas aeruginosa. In Program and Abstracts of the Forty third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Il, 2003. Abstract D-234, p. 174. American Society for Microbiology, Washington, DC, USA.
